<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03814031</url>
  </required_header>
  <id_info>
    <org_study_id>12156</org_study_id>
    <nct_id>NCT03814031</nct_id>
  </id_info>
  <brief_title>Hepatic Vein Flow During Orthotopic Liver Transplantation as Predictive Factor for Postoperative Graft Function</brief_title>
  <official_title>Hepatic Vein Flow Assessment With Transesophageal Echocardiography for Postoperative Graft Function Prediction in Orthotopic Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic vein flow (HVF) assessment using transesophageal echocardiography (TEE) has a&#xD;
      potential to predict postoperative graft function in orthotopic liver transplant (OLT).&#xD;
      Investigators will measure HVF using TEE and assess the correlation with postoperative graft&#xD;
      function indices such as early allograft dysfunction(EAD), prolonged INR, platelet, and total&#xD;
      bilirubin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During OLT, intraoperative TEE assessment of HVF (systolic and diastolic) were measured, and&#xD;
      adjusted with donor graft weight. This index, HVF index, was assessed for correlation with&#xD;
      EAD. HVF was calculated with hepatic vein area (cm2) x hepatic vein velocity (ml/s) in&#xD;
      systole and diastole during the neohepatic phase. Investigators did ROC analysis to assess&#xD;
      the predictive power for EAD, prolonged INR, platelet, and total bilirubin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EAD</measure>
    <time_frame>within the first 7 days status post OLT</time_frame>
    <description>Primary outcome was early allograft dysfunction (EAD), which was defined by the presence of one or more of the following: total bilirubin (t-bil) ≥ 10 mg/dL (171 μmol/L) or, INR ≥ 1.6 on day 7, and ALT/AST &gt; 2,000 IU/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>within 6-8 weeks post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged (&gt; 7 days) time to normalize total bilirubin (TIME t-bil), prolonged (&gt;7 days) time to normalize INR (TIME inr), and prolonged (&gt;7 days) time to normalize platelet count (TIME plt).</measure>
    <time_frame>&gt; 7 days post transplant</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">97</enrollment>
  <condition>Postoperative Graft Function</condition>
  <arm_group>
    <arm_group_label>EAD</arm_group_label>
    <description>Early allograft dysfunction (EAD), which was defined by the presence of one or more of the following: total bilirubin (t-bil) ≥ 10 mg/dL (171 μmol/L) or, INR ≥ 1.6 on day 7, and ALT/AST &gt; 2,000 IU/L within the first 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non EAD</arm_group_label>
    <description>No EAD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NO internvention</intervention_name>
    <description>NO internvention</description>
    <arm_group_label>EAD</arm_group_label>
    <arm_group_label>Non EAD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        OLT with piggy back technique&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Orthotopic liver transplants which uses TEE intraoperatively Must be Piggy back technique&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        TEE absolute contraindication patient refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshihisa Morita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HFHS</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Yoshihisa Morita</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>TEE</keyword>
  <keyword>orthotopic liver transplant</keyword>
  <keyword>EAD</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

